Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Other Non-Current Liabilities (2016 - 2020)

Historic Other Non-Current Liabilities for Niagen Bioscience (NAGE) over the last 10 years, with Q2 2020 value amounting to $250000.0.

  • Niagen Bioscience's Other Non-Current Liabilities fell 1467.58% to $250000.0 in Q2 2020 from the same period last year, while for Jun 2020 it was $250000.0, marking a year-over-year decrease of 1467.58%. This contributed to the annual value of $169000.0 for FY2019, which is 3854.55% down from last year.
  • Niagen Bioscience's Other Non-Current Liabilities amounted to $250000.0 in Q2 2020, which was down 1467.58% from $238000.0 recorded in Q1 2020.
  • In the past 5 years, Niagen Bioscience's Other Non-Current Liabilities ranged from a high of $503850.0 in Q3 2017 and a low of $155000.0 during Q3 2018
  • In the last 5 years, Niagen Bioscience's Other Non-Current Liabilities had a median value of $275000.0 in 2018 and averaged $286329.8.
  • As far as peak fluctuations go, Niagen Bioscience's Other Non-Current Liabilities crashed by 6328.27% in 2018, and later surged by 7970.3% in 2019.
  • Niagen Bioscience's Other Non-Current Liabilities (Quarter) stood at $389010.0 in 2016, then fell by 19.28% to $314000.0 in 2017, then dropped by 12.42% to $275000.0 in 2018, then tumbled by 38.55% to $169000.0 in 2019, then soared by 47.93% to $250000.0 in 2020.
  • Its last three reported values are $250000.0 in Q2 2020, $238000.0 for Q1 2020, and $169000.0 during Q4 2019.